Johnson & Johnson (JNJ)
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
The vast majority of investors don't have hundreds of thousands to bet on each stock.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.
Johnson & Johnson: Patience Will Be Rewarded
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, though below JNJ's historical average. However, I believe the market has also priced in these issues already.
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
Allocating 10% to 20% to dividend stocks balances growth-heavy portfolios, leveraging compounding returns to navigate geopolitical and monetary challenges.
